CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$4.45
-0.15 (-3.26%)
Open$4.60
Previous Close$4.60
Day High$4.78
Day Low$4.40
52W High$6.16
52W Low$1.60
Volume—
Avg Volume2.08M
Market Cap565.01M
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+342.0% upside
Current
$4.45
$4.45
Target
$19.67
$19.67
$12.33
$19.67 avg
$23.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.42M | 4.73M | 70.28M |
| Net Income | -131,936,619 | -231,693,574 | -10,926,196 |
| Profit Margin | -5,452.5% | -5,179.9% | -15.6% |
| EBITDA | -147,407,490 | -273,243,152 | -18,107,687 |
| Free Cash Flow | — | — | -6,087,830 |
| Rev Growth | -48.8% | -48.8% | +8.8% |
| Debt/Equity | 0.01 | 0.01 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |